Skip to content
Investment Visual
/
Backtest
Tools
Browse
Stocks
MRNA
Financials
Long-term debt
MRNA
Moderna, Inc.
Backtest
MRNA
Overview
Returns
Financials
Holders
Insiders
Summary
Statements
Income
Cash flow
Balance sheet
Cash
Long-term debt
Equity
Total assets
Total liabilities
Valuation
Shares and dividends
Costs
Long-term debt
Long-term debt, 2025
$590M
Annual
Quarterly
Long-term debt
Annual
Quarterly
Value
YoY
5Y
10Y
Max
Value
YoY
5Y
10Y
Max
Long-term debt by fiscal year
CSV
Period
On
Long-term debt
YoY
Filing
2025
2025
Dec 31, 2025
$590M
—
10-K, Feb 20, 2026
2024
2024
Dec 31, 2024
$0
—
10-K, Feb 20, 2026
More Moderna financials
Cash
Equity
Total assets
Total liabilities
Revenue
Gross profit
Long-term debt at other companies
LLY
Eli Lilly and Company
UNH
UnitedHealth Group Incorporated
JNJ
Johnson & Johnson
MDT
Medtronic plc
TMO
Thermo Fisher Scientific Inc.
ABBV
AbbVie Inc.
Tools
Return calculator